Stoke Therapeutics, Inc. $STOK is Skorpios Trust’s Largest Position

Skorpios Trust lowered its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 30.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,256,181 shares of the company’s stock after selling 1,000,000 shares during the quarter. Stoke Therapeutics accounts for about 99.7% of Skorpios Trust’s holdings, making the stock its biggest position. Skorpios Trust owned about 4.12% of Stoke Therapeutics worth $53,020,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in STOK. Corient Private Wealth LLC purchased a new position in shares of Stoke Therapeutics in the 2nd quarter valued at about $7,489,000. Assenagon Asset Management S.A. grew its position in Stoke Therapeutics by 67.3% during the third quarter. Assenagon Asset Management S.A. now owns 900,272 shares of the company’s stock worth $21,156,000 after buying an additional 362,299 shares during the period. Goldman Sachs Group Inc. increased its holdings in Stoke Therapeutics by 21.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock valued at $11,053,000 after buying an additional 293,072 shares in the last quarter. Opaleye Management Inc. increased its holdings in Stoke Therapeutics by 87.4% in the second quarter. Opaleye Management Inc. now owns 562,120 shares of the company’s stock valued at $6,380,000 after buying an additional 262,120 shares in the last quarter. Finally, Marshall Wace LLP lifted its position in shares of Stoke Therapeutics by 7.9% during the 2nd quarter. Marshall Wace LLP now owns 2,300,554 shares of the company’s stock valued at $26,111,000 after acquiring an additional 168,771 shares during the period.

Insider Activity

In other news, insider Barry Ticho sold 5,931 shares of the firm’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $25.72, for a total transaction of $152,545.32. Following the sale, the insider owned 7,195 shares in the company, valued at $185,055.40. This trade represents a 45.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Edward M. Md Kaye sold 13,430 shares of Stoke Therapeutics stock in a transaction on Monday, December 8th. The shares were sold at an average price of $32.27, for a total value of $433,386.10. Following the completion of the sale, the director directly owned 49,124 shares of the company’s stock, valued at approximately $1,585,231.48. This represents a 21.47% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 104,705 shares of company stock worth $3,070,910. 9.50% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on STOK shares. Loop Capital set a $35.00 price target on Stoke Therapeutics in a report on Monday, January 5th. UBS Group set a $50.00 target price on Stoke Therapeutics in a report on Monday, December 15th. Needham & Company LLC raised their price target on Stoke Therapeutics from $22.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, October 10th. JPMorgan Chase & Co. lifted their price target on Stoke Therapeutics from $15.00 to $25.00 and gave the stock a “neutral” rating in a research note on Monday, November 3rd. Finally, Wedbush increased their price objective on shares of Stoke Therapeutics from $32.00 to $36.00 and gave the company an “outperform” rating in a research note on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Stoke Therapeutics has an average rating of “Moderate Buy” and an average target price of $37.10.

Stoke Therapeutics Trading Up 0.1%

Stoke Therapeutics stock opened at $28.72 on Wednesday. The stock has a 50-day moving average price of $30.96 and a 200 day moving average price of $24.70. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $38.69. The stock has a market cap of $1.64 billion, a PE ratio of 42.87 and a beta of 1.10.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.11). The firm had revenue of $10.63 million during the quarter, compared to analysts’ expectations of $6.06 million. Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. On average, equities analysts predict that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.